Rigid gas permeable (RGP) contact lenses are made of materials with excellent oxygen permeability and wettability, so they not only improve oxygen permeability compared to existing lenses, but also provide correction of refractive errors and improved vision in irregular corneas such as keratoconus. However, the hard material of the lens along with hypoxia and hypercapnia of the cornea caused by wearing RGP contact lenses cause various physiological changes in the cornea. Physiological changes in the cornea that may occur when wearing RGP contact lenses include mucin balls, decreased corneal epithelial thickness and increased size, decreased epithelial barrier function, corneal erosion and staining, decreased keratocyte density, decreased corneal sensitivity, and stromal opacities, contact lens‐induced peripheral ulcers, endothelial blebs, increased endothelial polymegethism, and changes in corneal shape. It is necessary to know the performance of the RGP contact lenses being prescribed, be aware of the physiological changes in the cornea caused by wearing RGP contact lenses, and provide the correct lens prescription along with appropriate education to the patient.

Rigid gas permeable (RGP) contact lenses are made of materials with excellent oxygen permeability and wettability, so they not only improve oxygen permeability compared to existing lenses, but also provide correction of refractive errors and improved vision in irregular corneas such as keratoconus. However, the hard material of the lens along with hypoxia and hypercapnia of the cornea caused by wearing RGP contact lenses cause various physiological changes in the cornea. Physiological changes in the cornea that may occur when wearing RGP contact lenses include mucin balls, decreased corneal epithelial thickness and increased size, decreased epithelial barrier function, corneal erosion and staining, decreased keratocyte density, decreased corneal sensitivity, and stromal opacities, contact lens‐induced peripheral ulcers, endothelial blebs, increased endothelial polymegethism, and changes in corneal shape. It is necessary to know the performance of the RGP contact lenses being prescribed, be aware of the physiological changes in the cornea caused by wearing RGP contact lenses, and provide the correct lens prescription along with appropriate education to the patient.

Rigid gas permeable (RGP) contact lenses are made of materials with excellent oxygen permeability and wettability, so they not only improve oxygen permeability compared to existing lenses, but also provide correction of refractive errors and improved vision in irregular corneas such as keratoconus. However, the hard material of the lens along with hypoxia and hypercapnia of the cornea caused by wearing RGP contact lenses cause various physiological changes in the cornea. Physiological changes in the cornea that may occur when wearing RGP contact lenses include mucin balls, decreased corneal epithelial thickness and increased size, decreased epithelial barrier function, corneal erosion and staining, decreased keratocyte density, decreased corneal sensitivity, and stromal opacities, contact lens‐induced peripheral ulcers, endothelial blebs, increased endothelial polymegethism, and changes in corneal shape. It is necessary to know the performance of the RGP contact lenses being prescribed, be aware of the physiological changes in the cornea caused by wearing RGP contact lenses, and provide the correct lens prescription along with appropriate education to the patient.

Rigid gas permeable (RGP) contact lenses are made of materials with excellent oxygen permeability and wettability, so they not only improve oxygen permeability compared to existing lenses, but also provide correction of refractive errors and improved vision in irregular corneas such as keratoconus. However, the hard material of the lens along with hypoxia and hypercapnia of the cornea caused by wearing RGP contact lenses cause various physiological changes in the cornea. Physiological changes in the cornea that may occur when wearing RGP contact lenses include mucin balls, decreased corneal epithelial thickness and increased size, decreased epithelial barrier function, corneal erosion and staining, decreased keratocyte density, decreased corneal sensitivity, and stromal opacities, contact lens‐induced peripheral ulcers, endothelial blebs, increased endothelial polymegethism, and changes in corneal shape. It is necessary to know the performance of the RGP contact lenses being prescribed, be aware of the physiological changes in the cornea caused by wearing RGP contact lenses, and provide the correct lens prescription along with appropriate education to the patient.

From January l, l990 to June 30, l992, tota1 1,067 epidural anesthesia were evaluated retrospectively for physical status, level of anesthesia, agents of 1ocal anesthetics, complication and poatoperative pain control. The reaults were as follows: 1) Annual numbers of epidural aneathesia were 272 cases in 1990. 392 cases in 1991 and 403 cases in 1992 respectively. The number of epidural anesthesia was increaeing with years. 2) The most common site of epidural puncture level wae L(3-4) intervertebral space and mean depth from skin to epidural space was 4.88 cm. 3) The local anesthetics that used during epidural anesthesia were lidocaine(1%, 1.5%, 2%) and bupivacaine(0.25%, 0.375%. 0.5%). 4) The most common sensory level which were blocked by epidural anesthesia waa T(10) and most common complication was hypotension. 5) Postoperative pain control with epidural anestheaia was managed with continuous drug infusor after 1991, and it was managed with single bolus injection before 1991. In conclusion, epidural anesthesia is a safe regional anesthesia that will reduce the incidence of hypotension provided that careful control of the aensory level to be anesthetiaed is taken under consideration along with the age, physical status, site of operation, volume of local anesthetics and it is effective for the postoperative pain control with continuous infusion of morphine sulfate and local anesthetic through catheter.
Anesthesia ; Anesthesia, Conduction ; Anesthesia, Epidural* ; Anesthetics ; Anesthetics, Local ; Catheters ; Epidural Space ; Hypotension ; Incidence ; Infusion Pumps ; Morphine ; Pain, Postoperative ; Punctures ; Retrospective Studies ; Skin

Tofacitinib, a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, is metabolized through hepatic cytochrome P450 (CYP), specifically CYP3A1/2 and CYP2C11. Prolonged administration of rheumatoid arthritis medications is generally associated with an increased risk of renal toxicity. Loganin (LGN), an iridoid glycoside, has hepatorenal regenerative properties. This study investigates the potential of LGN to mitigate acute kidney injury (AKI) and its effects on the pharmacokinetics of tofacitinib in rats with cisplatin-induced AKI. Both intravenous and oral administration of tofacitinib to AKI rats significantly increased the area under the plasma concentration-time curve from time 0 to infinity (AUC) compared with control (CON) rats, an increase attributed to the decelerated non-renal clearance (CL NR) and renal clearance (CL R) of tofacitinib. Administration of LGN to AKI rats, however, protected kidneys from severe impairment, restoring the pharmacokinetic parameters (AUC, CL NR, and CL R) of tofacitinib to those observed in untreated CON rats, with partial recovery of kidney function, as evidenced by an increase in creatinine clearance.Possible interactions between drugs and natural components should be considered, especially when co-administering both a drug and a natural extract containing LGN or iridoid glycosides to patients with kidney injury.

Tofacitinib, a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, is metabolized through hepatic cytochrome P450 (CYP), specifically CYP3A1/2 and CYP2C11. Prolonged administration of rheumatoid arthritis medications is generally associated with an increased risk of renal toxicity. Loganin (LGN), an iridoid glycoside, has hepatorenal regenerative properties. This study investigates the potential of LGN to mitigate acute kidney injury (AKI) and its effects on the pharmacokinetics of tofacitinib in rats with cisplatin-induced AKI. Both intravenous and oral administration of tofacitinib to AKI rats significantly increased the area under the plasma concentration-time curve from time 0 to infinity (AUC) compared with control (CON) rats, an increase attributed to the decelerated non-renal clearance (CL NR) and renal clearance (CL R) of tofacitinib. Administration of LGN to AKI rats, however, protected kidneys from severe impairment, restoring the pharmacokinetic parameters (AUC, CL NR, and CL R) of tofacitinib to those observed in untreated CON rats, with partial recovery of kidney function, as evidenced by an increase in creatinine clearance.Possible interactions between drugs and natural components should be considered, especially when co-administering both a drug and a natural extract containing LGN or iridoid glycosides to patients with kidney injury.

Tofacitinib, a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, is metabolized through hepatic cytochrome P450 (CYP), specifically CYP3A1/2 and CYP2C11. Prolonged administration of rheumatoid arthritis medications is generally associated with an increased risk of renal toxicity. Loganin (LGN), an iridoid glycoside, has hepatorenal regenerative properties. This study investigates the potential of LGN to mitigate acute kidney injury (AKI) and its effects on the pharmacokinetics of tofacitinib in rats with cisplatin-induced AKI. Both intravenous and oral administration of tofacitinib to AKI rats significantly increased the area under the plasma concentration-time curve from time 0 to infinity (AUC) compared with control (CON) rats, an increase attributed to the decelerated non-renal clearance (CL NR) and renal clearance (CL R) of tofacitinib. Administration of LGN to AKI rats, however, protected kidneys from severe impairment, restoring the pharmacokinetic parameters (AUC, CL NR, and CL R) of tofacitinib to those observed in untreated CON rats, with partial recovery of kidney function, as evidenced by an increase in creatinine clearance.Possible interactions between drugs and natural components should be considered, especially when co-administering both a drug and a natural extract containing LGN or iridoid glycosides to patients with kidney injury.

Tofacitinib, a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, is metabolized through hepatic cytochrome P450 (CYP), specifically CYP3A1/2 and CYP2C11. Prolonged administration of rheumatoid arthritis medications is generally associated with an increased risk of renal toxicity. Loganin (LGN), an iridoid glycoside, has hepatorenal regenerative properties. This study investigates the potential of LGN to mitigate acute kidney injury (AKI) and its effects on the pharmacokinetics of tofacitinib in rats with cisplatin-induced AKI. Both intravenous and oral administration of tofacitinib to AKI rats significantly increased the area under the plasma concentration-time curve from time 0 to infinity (AUC) compared with control (CON) rats, an increase attributed to the decelerated non-renal clearance (CL NR) and renal clearance (CL R) of tofacitinib. Administration of LGN to AKI rats, however, protected kidneys from severe impairment, restoring the pharmacokinetic parameters (AUC, CL NR, and CL R) of tofacitinib to those observed in untreated CON rats, with partial recovery of kidney function, as evidenced by an increase in creatinine clearance.Possible interactions between drugs and natural components should be considered, especially when co-administering both a drug and a natural extract containing LGN or iridoid glycosides to patients with kidney injury.

The purpose of this study was to compare the changes of retentive force in different stud attachment systems for implant retained overdenture. Two commercially available attachments with different retentive forces were investigated: Kerator (pink, blue, red) and O-ring (orange, red). Two implant fixtures were vertically embedded in base mountings. Five pairs of each attachment were evaluated. A universal testing machine was used to evaluate the retentive force of two attachments during wear simulation. Surface characteristics of each attachment system were evaluated with scanning electron microscopy. Five pairs of each attachment were evaluated. Kerator pink showed the highest initial retention. After 2,500 cycles of wear-simulation, Kerator pink noted the largest decrease in retention. According to results of surface analysis, Worn surfaces were obtained in matrices and patrices. Heavy wears were observed in matrices. After 2 year-wear simulation, most attachments exhibited retention loss. Attachments using different kind of material exhibited dissimilar surface alterations.
Denture, Overlay* ; Microscopy, Electron, Scanning